Premium
Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1,576 patients in France
Author(s) -
Hausfater P.,
Cacoub P.,
Sterkers Y.,
Thibault V.,
Amoura Z.,
Nguyen L.,
Ghillani P.,
Leblond V.,
Piette J.C.
Publication year - 2001
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.1101
Subject(s) - medicine , hematology , chronic lymphocytic leukemia , lymphoma , hepatitis c virus , lymphoproliferative disorders , multiple myeloma , immunology , leukemia , hepatitis c , gastroenterology , context (archaeology) , virus , paleontology , biology
Context Discordant data have been reported about the prevalence of hepatitis C virus (HCV) infection in patients with lymphoproliferative diseases and the putative role of HCV in lymphomagenesis. Objective To assess the prevalence of HCV infection in patients admitted to a hematology department in Paris, France. Design Prospective, controlled study. Setting University medical center. Patients 813 patients admitted to the Hematology department (164 B‐cell non‐Hodgkin's lymphoma, 34 Hodgkin's diseases, 107 chronic lymphocytic leukemia, 54 multiple myeloma, 12 Waldenström's macroglobulinemia, 17 acute lymphoblastic leukemia, 6 hairy cell leukemia, 189 myeloproliferative diseases, 6 solid organ tumors, and 224 nonmalignant diseases) and 694 patients admitted to the Internal Medicine department (control group). Measurements All patients were tested for antibodies to HCV by a third‐generation enzyme‐linked immunosorbent assay. Results HCV antibodies were detected in 20 of 813 (2.46%) patients in Hematology including 11 of 394 (2.79%) patients with lymphoproliferative diseases, 3 of 164 (1.83%) B‐cell non‐Hodgkin's lymphoma, 2 of 107 (1.87%) chronic lymphocytic leukemia, 1 of 54 (1.85%) multiple myeloma, 1 of 189 (0.5%) myeloproliferative diseases, and 8 of 224 (3.57%) nonmalignant hematologic diseases. HCV antibodies were detected in 3 of 694 (0.43%) patients in the control group. HCV contamination preceded B‐cell non‐Hodgkin's lymphoma only in 2 of 3 HCV‐positive patients. Conclusion The prevalence of HCV infection was low (1.83%) in patients with B‐cell non‐Hodgkin lymphoma. HCV seems not to play a major role in the pathogenesis of B‐cell lymphoma in France. Cofactors should be stressed to explain geographical discrepancies. Am. J. Hematol. 67:168–171, 2001. © 2001 Wiley‐Liss, Inc.